Therapeutic drug monitoring of antithyroid drugs in pregnancy: The knowledge gaps

Therapeutic Drug Monitoring

Volumn 28, Issue 1, 2006, Pages 12-13

  Koren, Gideon ^a,b,d   Soldin, Offie ^c  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Antithyroid; Malformations; Pregnancy; Therapeutic drug monitoring; Thyrotoxicosis

Indexed keywords

ANTITHYROID AGENT; PROPYLTHIOURACIL; THIAMAZOLE;

BREAST FEEDING; DRUG CLEARANCE; DRUG MILK LEVEL; DRUG MONITORING; FETUS MALFORMATION; HUMAN; HYPERTHYROIDISM; PREGNANCY; PRIORITY JOURNAL; SHORT SURVEY; THYROTOXICOSIS; BLOOD; BREAST MILK; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CONGENITAL MALFORMATION; DRUG ADMINISTRATION; FEMALE; FETOMATERNAL TRANSFUSION; KNOWLEDGE; NEWBORN; REVIEW;

ABNORMALITIES, DRUG-INDUCED; ANTITHYROID AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HUMANS; INFANT, NEWBORN; KNOWLEDGE; MATERNAL-FETAL EXCHANGE; METHIMAZOLE; MILK, HUMAN; PREGNANCY; PROPYLTHIOURACIL; THYROTOXICOSIS;

EID: 33745495516     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000192135.54477.d9     Document Type: Short Survey

References (13)

1. Koren G, Bologa M, Long D, et al. Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester. Am J Obstet Gynecol. 1989;160:1190-1194.
2. Koren G, Bologa M, Pastuszak A. How women perceive teratogenic risk and what they do about it. Ann N Y Acad Sci. 1993;678:317-324.
3. Lazarus JH, Premawardhana LD. Screening for thyroid disease in pregnancy. J Clin Pathol. 2005;58:449-452.
4. Ohguni S, Notsu K, Kato Y. Triphasic changes in thyroid function in a patient with primary hypothyroidism in the course of pregnancy and the early post-partum period. Endocr J. 1997;44:581-587.
5. Mortimer RH, Cannell GR, Addison RS, et al. Methimazole and propylthiouracil equally cross the perfused human term placental lobule. J Clin Endocrinol Metab. 1997;82:3099-3102.
6. Gardner DF, Cruikshank DP, Hays PM, et al. Pharmacology of propylthiouracil (PTU) in pregnant hyperthyroid women: correlation of maternal PTU concentrations with cord serum thyroid function tests. J Clin Endocrinol Metab. 1986;62:217-220.
7. Momotani N, Noh JY, Ishikawa N, et al. Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves' hyperthyroidism. J Clin Endocrinol Metab. 1997;82:3633-3636.
8. Di Gianantonio E, Schaefer C, Mastroiacovo PP, et al. Adverse effects of prenatal methimazole exposure. Teratology. 2001;64:262-266.
9. Gilbert ME, Paczkowski C: Propylthiouracil (PTU)-induced hypothyroidism in the developing rat impairs synaptic transmission and plasticity in the dentate gyrus of the adult hippocampus. Brain Res Dev Brain Res. 2003;145:19-29.
10. Mujtaba Q, Burrow GN. Treatment of hyperthyroidism in pregnancy with propylthiouracil and methimazole. Obstet Gynecol. 1975;46:282-286.
11. Azizi F, Khamseh ME, Bahreynian M, et al. Thyroid function and intellectual development of children of mothers taking methimazole during pregnancy. J Endocrinol Invest. 2002;25:586-589.
12. Momotani N, Yamashita R, Makino F, et al. Thyroid function in wholly breast-feeding infants whose mothers take high doses of propylthiouracil. Clin Endocrinol (Oxf). 2000;53:177-181.
13. Lee A, Moretti ME, Collantes A, et al. Choice of breastfeeding and physicians' advice: a cohort study of women receiving propylthiouracil. Pediatrics. 2000;106:27-30.